Pradžia › Ewingo sarkoma › Mičiganas
Ewingo sarkoma klinikiniai tyrimai Mičiganas
8 tyrimai dėl Ewingo sarkoma ieško dalyvių vietose Mičiganas.
Miestai Mičiganas
Oficialus tyrimo tekstas (anglų kalba)
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
- Helen DeVos Children's Hospital, Grand Rapids
Renkami dalyviai1 fazė
Amžius 1 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07194044Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Corewell Health ( Site 1001), Grand Rapids
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- University of Michigan, Ann Arbor
- START Midwest Michigan, PC, Grand Rapids
Renkami dalyviai1 fazė
Amžius nuo 12 iki 85 · Visoms lytims · Atnaujinta 2026-09-08 · NCT03715933Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Children's Hospital of Michigan/Wayne State University, Detroit
Renkami dalyviai1/2 fazė
Iki 30 metų · Visoms lytims · Atnaujinta 2026-09-03 · NCT06541262Lurbinectedin in FET-Fused Tumors
- University of Michigan, Ann Arbor
Renkami dalyviai1/2 fazė
Amžius 10 ir vyresni · Visoms lytims · Atnaujinta 2026-09-02 · NCT05918640Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- C S Mott Children's Hospital, Ann Arbor
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT04851119A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
- William Beaumont University Hospital, Royal Oak
Renkami dalyviai
Amžius 13 ir vyresni · Visoms lytims · Atnaujinta 2026-02-06 · NCT06387485Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Corewell Health, Grand Rapids
Renkami dalyviai1/2 fazė
Amžius nuo 2 iki 30 · Visoms lytims · Atnaujinta 2026-02-03 · NCT05734066Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.